Skip to main content
SpringerLink
Log in

Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Controversial data were reported concerning fasting ghrelin (decreased, normal or elevated) in polycystic ovary syndrome (PCOS). The aim of our study was to clarify ghrelin levels in non-obese, overweight, and obese PCOS patients; to investigate the effect of acute insulin infusion on ghrelin in PCOS as a chronic insulin-resistant state, with and without the impact of obesity, and to examine ghrelin-androgen interaction. In that order, we evaluated 1) ghrelin levels among 8 non-obese patients with PCOS [body mass index (BMI): 20.52±1.31 kg/m2], 8 overweight and obese patients with PCOS (BMI: 34.36±6.53 kg/m2) and their respective controls, 2) ghrelin suppression during euglycemic hyperinsulinemic clamp, and 3) ghrelin-androgen interrelationship. After overnight fast, 2-h euglycemic hyperinsulinemic clamp, was performed in all investigated women. Fasting ghrelin was significantly lower in non-obese PCOS than in controls (64.74±25.69 vs 108.36±52.60; p<0.05) as well as in overweight and obese PCOS in comparison with controls (38.71 ± 14.18 vs 98.77± 40.49; p<0.05). Insulin infusion significantly suppressed ghrelin in all subgroups of investigated women. Analysis of variance for repeatable measures confirmed that there was no significant difference in pattern of response between PCOS and controls. In conclusion, women with PCOS had lower fasting ghrelin and decreased insulin sensitivity independently of their BMI, compared to the controls. In addition, there were no differences between fasting ghrelin levels among non-obese, overweight, and obese women with PCOS. During euglycemic hyperinsulinemic clamp, ghrelin decreased in all studied groups to a similar extent, implying that, compared to chronic hyperinsulinemia, acute hyperinsulinemia reduces ghrelin levels independently of the degree of insulin resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656–60.

    Article  CAS  PubMed  Google Scholar 

  2. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increase food intake in humans. J Clin Endocrinol Metab 2001, 86: 5992–5.

    Article  CAS  PubMed  Google Scholar 

  3. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschöp M. Mini-review: ghrelin and the regulation of energy balance — A hypothalamic perspective. Endocrinology 2001, 142: 163–9.

    Google Scholar 

  4. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000, 407: 908–13.

    Article  PubMed  Google Scholar 

  5. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effects of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87: 240–4.

    Article  CAS  PubMed  Google Scholar 

  6. Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 4607–10.

    Article  PubMed  Google Scholar 

  7. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002, 87: 5625–9.

    Article  CAS  PubMed  Google Scholar 

  8. Moran LJ, Noakes M, Clifton PM, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004, 89: 3337–44.

    Article  CAS  PubMed  Google Scholar 

  9. Panidis D, Farmakiotis D, Koliakos G, et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Human Reprod 2005, 20: 2127–32.

    Article  CAS  Google Scholar 

  10. Orio F Jr, Lucidi P, Palomba S, et al. Circulating ghrelin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 942–5.

    Article  CAS  PubMed  Google Scholar 

  11. Wasko R, Komarowska H, Warenik-Szymankiewicz A, Sowinski J. Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. Horm Metab Res 2004, 36: 170–3.

    Article  CAS  PubMed  Google Scholar 

  12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocrine Rev 1997, 18: 774–800.

    CAS  Google Scholar 

  13. Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin: a double blind, placebo-controlled crossover clamp study. Diabetes 2003, 52: 16–20.

    Article  CAS  PubMed  Google Scholar 

  14. Leonetti F, Iacobellis G, Riabaudo MC, et al. Acute insulin infusion decreases plasma ghrelin levels in uncomplicated obesity. Reg Pept 2004, 122: 179–83.

    Article  CAS  Google Scholar 

  15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19–25.

    Google Scholar 

  16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000, 23,(Suppl 1): S4–19.

    Google Scholar 

  17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214–23.

    CAS  PubMed  Google Scholar 

  18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function frm fasting glucose and insulin concentration in man. Diabetologia 1985, 28: 412–9.

    Article  CAS  PubMed  Google Scholar 

  19. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab 2006, 20: 177–91.

    Article  CAS  PubMed  Google Scholar 

  20. Glintborg D, Andersen H, Hagen C, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006, 155: 337–45.

    Article  CAS  PubMed  Google Scholar 

  21. Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003, 284: E313–6.

    CAS  PubMed  Google Scholar 

  22. Saad MF, Bernaba B, Hwu CM, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002, 87: 3997–4000.

    Article  CAS  PubMed  Google Scholar 

  23. Ikezaki A, Hosoda H, Ito K, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI1, but not with leptin, in obese children and adolescents. Diabetes 2002, 51: 3408–11.

    Article  CAS  PubMed  Google Scholar 

  24. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal weight but not obese subjects. J Clin Endocrinol Metab 2005, 90: 1068–71.

    Article  PubMed  Google Scholar 

  25. Mohlig M, Spranger J, Otto B, Ristow M, Tschöp M, Pfeiffer AF. Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans. J Endocrinol Invest 2002, 25: RC36–8.

    CAS  PubMed  Google Scholar 

  26. McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese inulin-sensitive controls. J Clin Endocrinol Metab 2004, 89: 1630–5.

    Article  CAS  PubMed  Google Scholar 

  27. van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004, 25: 426–57.

    Article  PubMed  Google Scholar 

  28. St-Pierre DH, Karelis AD, Coderre L, et al. Association of acylated and nonacylated Ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J Clin Endocrinol Metab 2007, 92: 264–9.

    Article  CAS  PubMed  Google Scholar 

  29. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006, 91: 4842–8.

    Article  CAS  PubMed  Google Scholar 

  30. Porte D Jr, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54: 1264–76.

    Article  CAS  PubMed  Google Scholar 

  31. Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005, 16: 59–65.

    Article  CAS  PubMed  Google Scholar 

  32. Pliquett RU, Führer D, Falk S, Zysset S, von Cramon DY, Stumvoll M. The effects of insulin on the central nervous system-focus on appetite regulation. Horm Metab Res 2006, 38: 442–6.

    Article  CAS  PubMed  Google Scholar 

  33. Ueno M, Carvalheira JB, Oliveira RL, Velloso LA, Saad MJ. Circulating ghrelin concentrations are lowered by intracerebroventricular insulin. Diabetologia 2006, 49: 2449–52.

    Article  CAS  PubMed  Google Scholar 

  34. Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002, 107: 63–9.

    Article  CAS  PubMed  Google Scholar 

  35. Caixas A, Bashore C, Nash W, Pl-Sunyer FX, Laferrere B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 2002, 87: 1902–6.

    Article  CAS  PubMed  Google Scholar 

  36. Ott V, Fasshauer M, Dalski A, et al. Direct peripheral effects of ghrelin includes suppression of adiponectin expression. Horm Metab Res 2002, 34: 640–5.

    Article  CAS  PubMed  Google Scholar 

  37. Ravussin E, Tschöp M, Morales S, Bouchard C, Heiman ML. Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 2001, 86: 4547–51.

    Article  CAS  PubMed  Google Scholar 

  38. Kalra SP, Ueno N, Kalra PS. Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. J Nutr 2005, 135: 1331–5.

    CAS  PubMed  Google Scholar 

  39. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998, 395: 763–70.

    Article  CAS  PubMed  Google Scholar 

  40. Bagnasco M, Kalra PS, Kalra SP. Ghrelin and leptin pulse discharge in fed and fasted rats. Endocrinology 2002, 143: 726–9.

    Article  CAS  PubMed  Google Scholar 

  41. Tschöp M, Weyer C, Tataranni A, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50: 707–9.

    Article  PubMed  Google Scholar 

  42. Gambineri A, Pagotto U, Tschöp M, et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 2003, 26: 629–34.

    Article  CAS  PubMed  Google Scholar 

  43. Tena-Sempere M, Barreiro MI, Gonzáles IC, et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology 2002, 143: 717–25.

    Article  CAS  PubMed  Google Scholar 

  44. Dahan MH, Goldstein J. Serum sex-hormone binding globulin levels show too much variability to be used effectively as a screening marker for insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006, 86: 934–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Metabolic Disorders in Endocrinology, Institute of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Dr Subotica 13, 11000, Belgrade, Serbia

    D. Micic MD, PhD, M. Sumarac-Dumanovic, A. Kendereski, G. Cvijovic, S. Zoric & D. Pejkovic

  2. Institute of Gynecology, and Obstetrics, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia

    J. Micic

  3. Institute of Medical Statistics, School of Medicine, University of Belgrade, Belgrade, Serbia

    N. Milic

  4. Department of Endocrinology, University of Santiago de Compostela, Santiago de Compostela, Spain

    C. Dieguez & F. F. Casanueva

Authors
  1. D. Micic MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Sumarac-Dumanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Kendereski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Cvijovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Zoric
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Pejkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Micic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Milic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Dieguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. F. Casanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Micic MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Micic, D., Sumarac-Dumanovic, M., Kendereski, A. et al. Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome. J Endocrinol Invest 30, 820–827 (2007). https://doi.org/10.1007/BF03349222

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349222

Key-words

Search

Navigation